AstraZeneca plans to unveil data at this year’s American Society of Clinical Oncology (ASCO) conference that could expand the number of patients who could be treated with two of its most im
The chances of former shareholders in Celgene missing out on the big pay-out from their contingent value right (CVR) deal with Bristol-Myers Squibb have risen sharply, aft
NICE has recommended NHS funding for a duo of cancer drugs, giving final guidance on new options for certain patients with follicular lymphoma and lung cancer.
Sanofi is trumpeting new data for its anti-CD38 drug Sarclisa as it tries to capture market share from Johnson & Johnson’s blockbuster Darzalex in the multiple myeloma mark
Eli Lilly now has a second approved drug from its takeover of Loxo Oncology last year after getting the go-ahead from the FDA for RET inhibitor Retevmo.
AstraZeneca and Merck & Co have hit back at their rival GlaxoSmithKline after the FDA allowed Lynparza to be used in a wider group of ovarian cancer patients when combined with Roche’s